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Genes encoding angiotensin-converting enzymes (Ace and Ace2)
are essential for heart function regulation. Cardiac stress enhances
Ace, but suppresses Ace2, expression in the heart, leading to a net
production of angiotensin II that promotes cardiac hypertrophy
and fibrosis. The regulatory mechanism that underlies the Ace2-
to-Ace pathological switch, however, is unknown. Here we report
that the Brahma-related gene-1 (Brg1) chromatin remodeler and
forkhead box M1 (FoxM1) transcription factor cooperate within
cardiac (coronary) endothelial cells of pathologically stressed hearts
to trigger the Ace2-to-Ace enzyme switch, angiotensin I-to-II con-
version, and cardiac hypertrophy. In mice, cardiac stress activates
the expression of Brg1 and FoxM1 in endothelial cells. Once acti-
vated, Brg1 and FoxM1 form a protein complex on Ace and Ace2
promoters to concurrently activate Ace and repress Ace2, tipping
the balance to Ace2 expression with enhanced angiotensin II pro-
duction, leading to cardiac hypertrophy and fibrosis. Disruption of
endothelial Brg1 or FoxM1 or chemical inhibition of FoxM1 abol-
ishes the stress-induced Ace2-to-Ace switch and protects the heart
from pathological hypertrophy. In human hypertrophic hearts,
BRG1 and FOXM1 expression is also activated in endothelial cells;
their expression levels correlate strongly with the ACE/ACE2 ratio,
suggesting a conserved mechanism. Our studies demonstrate a mo-
lecular interaction of Brg1 and FoxM1 and an endothelial mecha-
nism of modulating Ace/Ace2 ratio for heart failure therapy.
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Despite modern cardiac care, heart failure remains the leadingcause of death, with a mortality rate of ∼50% within 5 y of
diagnosis (1). New mechanisms and therapeutic strategies for heart
failure are needed. Most studies focus on the cardiomyocytes’
maladaptive response to pathological stress as a cause of heart
failure; little is known about how endothelial cells within the heart
react to pathological stress to modify heart function. In heart failure
patients without coronary artery disease, coronary endothelial dys-
function correlates with adverse cardiac remodeling, contractile
abnormalities, and brain natriuretic peptide (BNP) levels (2–6);
however, the endothelial function of peripheral arteries is preserved
in those patients (3). These findings suggest that localized endo-
thelial dysfunction in the heart is crucial for cardiac remodeling and
hypertrophy. This aspect of cardiac endothelial function, however, is
not well understood, and its clinical potential as a therapeutic target
has not been sufficiently developed (7).
Heart function regulation requires angiotensin peptides (8),
which are predominantly produced within the heart. Angiotensin
peptides have much higher concentrations in the heart than in the
plasma (9–11): The interstitial concentration of angiotensin II (Ang
II) of the heart is ∼100-fold more than that of plasma (11, 12).
Within the heart, >90% of Ang I is synthesized locally, and >75%
of Ang II is produced by enzymatic conversion of the local cardiac
Ang I (13, 14). Cardiac (coronary) endothelial cells are the primary
source that produces angiotensin-converting enzymes (Ace and
Ace2) to control angiotensin peptide production (8, 15). Ace and
Ace2 are tethered to endothelial cell membrane or secreted into the
interstitial space, where these enzymes process Ang I and II pep-
tides. Biochemically, Ace converts the decapeptide Ang I (1–12) to
octapeptide Ang II (1–10), whereas Ace2 degrades Ang II to form
Ang-(1–7) (16) and cleaves Ang I into Ang-(1–9) (17). Functionally,
Ang II is a potent stimulant of cardiac hypertrophy and fibrosis
(8); conversely, Ang-(1–7) and Ang-(1–9) inhibit Ang II’s cardiac
effects to maintain heart function (8, 18). Therefore, Ace and Ace2
counteract each other to regulate heart function.
When the heart is pathologically stressed, Ace is up-regulated
(19) and Ace2 down-regulated (20, 21), tipping the balance to
Ace dominance with enhanced Ang II and reduced Ang-(1–7) and
-(1–9) production. Such Ace/Ace2 perturbation contributes to the
development of hypertrophy and heart failure. Inhibition of Ace
(22) or overexpression ofAce2 protects the heart from stress-induced
failure (20); conversely, Ace2 knockout mice exhibit heart dysfunc-
tion (23). Therefore, Ace promotes cardiac pathology (22), whereas
Ace2 inhibits cardiomyopathy (20, 23). Balancing Ace/Ace2 is thus
critical for maintaining heart function.
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It is unclear how Ace and Ace2 expression is controlled by en-
dothelial cells within the heart. Gene regulation requires control
at the level of chromatin, which provides a dynamic scaffold to
package DNA and dictates accessibility of DNA sequence to
transcription factors. Here we show that Brahma-related gene-1
(Brg1), an essential ATPase subunit of the BAF chromatin-
remodeling complex (24), is activated by pathological stress within
the endothelium of mouse hearts to control Ace and Ace2 ex-
pression. Brg1 complexes with the forkhead box transcription
factor forkhead box M1 (FoxM1), which has both transactivating
and repressor domains for transcription regulation, to bind to Ace
and Ace2 promoters to simultaneously activate Ace and repress
Ace2 transcription. Mice with endothelial Brg1 deletion or with
FoxM1 inhibition or genetic disruption show resistance to stress-
induced Ace/Ace2 switch, cardiac hypertrophy, and heart dys-
function. In human hypertrophic hearts, BRG1 and FOXM1 are
also highly activated, and their activation correlates strongly with
the ACE/ACE2 ratio and disease severity, indicating a conserved
endothelial mechanism for human cardiomyopathy. Brg1 and
FoxM1 are therefore essential endothelial mediators of cardiac
stress that triggers pathological hypertrophy. Given the lack of
ACE2 drugs that limit full clinical exploitation of this pathway,
targeting the Brg1–FoxM1 complex may offer an alternative
strategy for concurrent ACE and ACE2 control in heart failure
therapy. Furthermore, the studies demonstrated a molecular in-
teraction between Brg1 and FoxM1 in gene control, which pro-
vides novel insights into the mechanisms of FoxM1-mediated
organ development and oncogenic processes (25–27).
Results
Dynamic Changes of Endothelial Factors that Contribute to Cardiac
Hypertrophy. To identify endothelial factors that might contribute
to cardiomyopathy, we surveyed a number of endothelial genes
for their changes of expression after left ventricular pressure
overload generated by transaortic constriction (TAC) (24, 28).
TAC-induced heart dysfunction was verified by echocardiogra-
phy and molecular markers Myh6, Myh7, Anf, Bnp, and Serca2a
(Figs. S1 A and B and S2 A–D). By performing reverse transcription
and quantitative PCR (RT-qPCR) of left ventricles (LVs), we ex-
amined the expression of the following cardiac endothelial factors
with or without TAC: eNos, Et-1, Adamts1, Hdac7, Nrg1, Ace, and
Ace2 (29). Within 7 d after TAC, Et-1 and Ace were induced 2.0-
and 2.1-fold in LVs, whereas Enos and Ace2 were reduced by 46%
and 43%, respectively (Fig. 1A). Adamts1, Hdac7, and Nrg1 had no
significant changes.
Given that Ace and Ace2 encode enzymes that are critical for
heart function (20–23, 29), we focused on the control of Ace and
Ace2 expression in TAC-stressed hearts. Immunostaining showed
that Ace proteins were present at low levels in healthy hearts, but
up-regulated in the endothelium of stressed hearts (Fig. 1 B and C
and Fig. S1 C and D). In contrast, Ace2 proteins were present at
high levels in the endothelium of healthy hearts, but down-regulated
in TAC-stressed hearts (Fig. 1 D and E). To further verify the op-
posite changes of Ace and Ace2 in endothelial cells, we used anti-
CD31 magnetic beads to isolate endothelial cells from hearts after
7 d of sham or TAC operation (30) (Fig. S1 E and F). Immuno-
staining with anti-CD31/Pecam showed that endothelial cells con-
stituted >90% of the sorted cells (Fig. S1 E and F). Western blot
analysis confirmed that Ace proteins were up-regulated to 2.0-fold
and Ace2 proteins reduced by 46%, with the ratio of Ace/Ace2
proteins changed by 3.7-fold in endothelial cells of the stressed
hearts (Fig. 1 H and I). Such Ace and Ace2 misregulation was also
present after 2 and 4 wk of TAC (Fig. S2).
With the view that Ace is known to promote cardiac pathol-
ogy (22), whereas Ace2 inhibits cardiomyopathy (20, 23), such op-
posite expression dynamics indicates that a loss of balance between
Ace and Ace2 in pressure-stressed hearts is crucial for the devel-
opment of pathological hypertrophy. Furthermore, the magnitude
of stress-induced changes in Ace and Ace2 proteins was compara-
ble to that of mRNA (Fig. 1 A and I), indicating that the primary
regulation of Ace and Ace2 in stressed hearts occurs at the tran-
scription level.
Endothelial Brg1 Is Essential for Cardiac Hypertrophy and Dysfunction.
Given that gene-transcription control requires chromatin regula-
tion and that the chromatin remodeler Brg1 is known to control
the pathologicalMyh6/Myh7 switch in stressed cardiomyocytes (24,
28), we hypothesized that Brg1, like in the control of the Myh6/
Myh7 switch, could function in endothelial cells to control the Ace/
Ace2 switch in stressed hearts. Immunostaining showed that Brg1
was expressed at a minimal/low level in endothelial cells of healthy
adult hearts. However, when the hearts were stressed by TAC,
Brg1 was up-regulated in the nuclei of both cardiomyocytes and
endothelial cells (Fig. 1 G and I). To compare Brg1 expression in
cardiomyocytes and endothelial cells, we isolated these two types
of cells from sham or TAC-stressed hearts (30) (Figs. S1 E and F
and S3A). We found comparable changes of Brg1 expression in
those two cell types. TAC increased Brg1 mRNA by ∼1.6-fold and
Brg1 protein by twofold in both cardiomyocytes and endothelial
cells (Fig. S3 B–D). Although Brg1 activation in cardiomyocytes is
crucial for the development of cardiac hypertrophy (24, 28), the
function of Brg1 in the endothelium of hypertrophic hearts
was unknown.
To test the role of endothelial Brg1 in stressed hearts, we used a
tamoxifen-inducible SclCreERT mouse line (31) to induce endo-
thelial Brg1 deletion in mice that carried floxed alleles of the Brg1
gene (Brg1fl) (32). Immunostaining showed that tamoxifen treat-
ment for 5 d (0.1 mg per gram of body weight, oral gavage once
every other day, three doses total) before the TAC surgery was
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Fig. 1. Stress-induced changes of endothelial Ace, Ace2, and Brg1 in the
hearts. (A) qRT-PCR analysis of eNos, Et-1, Adamts1, Hdac7, Nrg1, Ace, and Ace2
in the mice heart ventricles after sham or TAC operation. n = 5 mice per group.
P value: Student’s t test. Error bar: SEM. (B and C) Coimmunostaining of Ace
(red, arrows) and Pecam (green, labeling endothelial cells) in left ventricles 7 d
after sham (B) or TAC (C) operation. Blue, DAPI nuclear stain. (Scale bars,
10 μm.) (D and E) Coimmunostaining of Ace2 (red, arrows) and Pecam (green,
labeling endothelial cells) in left ventricles 7 d after sham (D) or TAC (E) oper-
ation. Blue, DAPI nuclear stain. (Scale bars, 10 μm.) (F and G) Coimmunostaining
of Brg1 (red) and Pecam (green, labeling endothelial cells) in left ventricles 7 d
after sham (F) or TAC (G) operation. Blue, DAPI nuclear stain. Arrows, Brg1 in
endothelial cell nuclei; arrowheads, Brg1 in myocardial cell nuclei. (Scale bars,
10 μm.) (H and I) Western blot analysis (H) and quantitation (I) of Ace, Ace2, and
Brg1 proteins in cardiac endothelial cells isolated from mouse hearts 7 d after
sham or TAC operation. P value: Student’s t test. Error bar: SEM.
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sufficient to activate a β-galactosidase reporter (R26R) and to dis-
rupt Brg1 expression in endothelial cells, but not cardiomyocytes,
of TAC-stressed hearts (Fig. 2 A–D). We then used TAC to pressure-
overload the heart and induce hypertrophy in littermate control
(SclCreER;Brg1fl/+ or Brg1fl/fl) and mutant SclCreERT;Brg1fl/fl mice
with or without tamoxifen treatment. Left ventricular fractional
shortening (FS) changes were followed by echocardiography (Fig.
S4A). Four weeks after TAC, the control mice developed larger
hearts than those of SclCreER;Brg1fl/flmice lacking endothelial Brg1
(Fig. 2E). Analysis of the cardiac mass (ventricle–body weight ra-
tio) showed an ∼50% reduction of hypertrophy (from 77% to 41%)
in SclCreERT;Brg1fl/fl mice (Fig. 2F). Cell size measurement by
wheat germ agglutinin (WGA) staining revealed ∼70% reduction
of cardiomyocyte size (from 74% to 21%) in SclCreERT;Brg1fl/flmice
(Fig. 2G and Fig. S4 B–E). There was also a dramatic reduction of
interstitial fibrosis in the SclCreERT;Brg1fl/fl mice (Fig. 2 H and I).
Within 4 wk after TAC, SclCreERT;Brg1fl/fl mice showed 23% im-
provement of left ventricular FS (P < 0.01; Fig. 2J and Fig. S4A).
To further determine cardiac function, we inserted a catheter
from the right carotid artery retrograde into the LV to measure its
pressure and volume (Fig. 2K). The in vivo catheterization showed
that TAC increased the peak LV systolic pressure from 100 to
150 mmHg (Fig. 2K), with a peak pressure overload of ∼50 mmHg.
This LV pressure overload was comparable between the control
and mutant hearts (Fig. 2L). The peripheral systolic pressure (right
carotid artery) was identical to that of LV and had no difference
between control and mutant mice. Endothelial Brg1 deletion
greatly improved the function of TAC-stressed hearts. SclCreERT;
Brg1fl/fl mice exhibited much better cardiac function 4 wk after
TAC. Ejection fraction (EF) improved by 49% (P < 0.001) (Fig.
2M); preload-adjusted maximal power (plPwr) by 38% (P = 0.04)
(Fig. 2N); stroke volume (SV) by 35% (P = 0.02) (Fig. 2O); and
stroke work (SW) by 20% (P = 0.03) (Fig. 2P). Also, SclCreERT;
Brg1fl/fl mice had less dilated hearts, with end-systolic volume
(ESV) reduced by 32% (P < 0.01) (Fig. 2Q) and end-diastolic
volume (EDV) reduced by 15% (P = 0.02) and normalized (Fig.
2R). Both the LV contractility and volume measurement indicate a
major improvement in systolic function of the heart. Furthermore,
SclCreERT;Brg1fl/fl hearts had greatly improved diastolic function.
This result was evidenced by the reduction of isovolumic relaxation
time constant tau by 42.3% (P = 0.01) (Fig. 2S) and end-diastolic
pressure (EDP) by 21% (P = 0.03) (Fig. 2T). As a result of systolic
and diastolic functional improvement, SclCreERT;Brg1fl/fl mice
showed a 33% (P = 0.02) increase of cardiac output (CO) (Fig.
2U). Consistent with the functional improvement of TAC-operated
SclCreERT;Brg1fl/fl mice, molecular markersMyh6 and Serca2a were
significantly increased, whereas the stress markers Myh7, Anf, and
Bnp were much reduced (Fig. S4F). This result is consistent with
the resistance of SclCreERT;Brg1fl/fl to TAC-induced heart failure.
Overall, endothelial Brg1-null mice had a 50–70% reduction of
cardiac hypertrophy, minimal/absent interstitial fibrosis, and re-
duction of heart functional decline after TAC. These findings in-
dicate that the Brg1 is activated by stress in cardiac endothelial
cells to trigger hypertrophy.
Endothelial Brg1 Controls Ace/Ace2 Expression and Ang I/II Metabolism.
Given that defective angiogenesis might contribute to cardiac
hypertrophy and failure (33), we examined cardiac vessel density
to test whether endothelial Brg1 was essential for angiogenesis in
stressed hearts. By Pecam staining, we found no difference in
vascular density of control and SclCreERT;Brg1fl/fl hearts treated
with tamoxifen and TAC (Fig. S5 A–E).
We then tested whether endothelial Brg1 controlled changes of
Ace and Ace2 in stressed hearts. By RT-qPCR of heart ventricles,
we examined the expression of eNos, Et1, Adamts1, Hdac7, Nrg1,
Ace, and Ace2 in tamoxifen-treated control and SclCreERT;Brg1fl/fl
hearts with or without TAC. Among these genes and after TAC,
the stress-induced opposite changes of Ace and Ace2 were evident
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Fig. 2. Endothelial Brg1 is essential for stress-induced cardiac hypertrophy
and dysfunction. (A and B) β-galactosidase (X-gal) staining (blue) of SclCreERT;
R26R mouse hearts without (A) or with (B) 5 d of tamoxifen (Tam) treatment.
Arrow, endothelial cells. (Scale bar, 10 μm.) (C and D) Coimmunostaining of
Brg1 (red) and Pecam (green, labeling endothelial cells) in SclCreERT;Brg1fl/fl
hearts 7 d after TAC without (C) or with (D) 5-d tamoxifen treatment. Blue,
DAPI nuclear stain. Arrows, endothelial cell nuclei; arrowheads, myocardial cell
nuclei. (Scale bars, 10 μm.) (E) Gross picture of hearts harvested 4 wk after
sham or TAC operation in control and SclCreERT;Brg1fl/fl mice treated with ta-
moxifen. (Scale bar, 2 mm.) (F) Quantitation of ventricle–body weight ratio in
control (Ctrl) and SclCreERT;Brg1fl/fl (Mut) mice 4 wk after sham or TAC oper-
ation. P value: Student’s t test. Error bar: SEM. (G) Quantitation of car-
diomyocyte size by wheat germ agglutinin (WGA) staining in control and
SclCreERT;Brg1fl/fl mice 4 wk after sham or TAC operation. (H and I) Trichrome
staining of cardiac fibrosis in control (H) and SclCreERT;Brg1fl/fl (I) mice 4 wk
after TAC operation. Red, cardiomyocytes; blue, fibrosis. Arrows, interstitial
space. (Scale bars, 50 μm.) (J) Echocardiographic measurement of fractional
shortening (FS) of the left ventricle after 4 wk of TAC. (K) Representative left
ventricular (LV) pressure–volume (PV) loops taken after cardiac catheterization
of control (Ctrl) and SclCreERT; Brg1fl/fl (Mut) mice 4 wk after sham or TAC
operation. (L–P) Quantitation of left ventricular systolic pressure (L), ejection
fraction (EF; M), preload-adjusted maximal power (plPwr; N), stroke volume
(SV; O), and stroke work (SW; P) 4 wk after sham or TAC operation. Ctrl,
control mice; Mut, SclCreERT; Brg1fl/fl mice. (Q–U) Quantitation of end-systolic
volume (ESV; Q), end-diastolic volume (EDV; R), Tau (S), end-diastolic pressure
(EDP; T), and cardiac output (CO; U) 4 wk after sham or TAC operation. Ctrl,
control mice; Mut, SclCreERT; Brg1fl/fl mice.
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in the control mice, with TAC increasing Ace/Ace2 ratio by
4.3-fold (Fig. 3A). However, such Ace/Ace2 changes were elimi-
nated in the TAC-stressed hearts of SclCreERT;Brg1fl/fl mice (Fig.
3A and Fig. S5 F and G), indicating that endothelial Brg1 is es-
sential for Ace up-regulation and Ace2 down-regulation in stressed
hearts. In contrast, the changes of other endothelial genes (eNos,
Et1, Adamts1, Hdac7, and Nrg1) were not affected by endothelial
Brg1 (Fig. S5H). These data suggest a degree of Brg1 specificity in
control of the Ace/Ace2 switch. Consistently, immunostaining
showed that Brg1 was required for the pathological switch of Ace
and Ace2 proteins in the heart endothelium. TAC-induced Ace
protein up-regulation and Ace2 down-regulation were essentially
abolished in the SclCreERT;Brg1fl/fl hearts (Fig. 3 B–I). These
findings were confirmed by Western blot quantitation of Ace and
Ace2 in heart protein extracts from the control and mutant mice
(Fig. 3 J and K). Furthermore, consistent with the Brg1-mediated
control of the Ace/Ace2 ratio, the TAC-induced Ang I reduction
and Ang II increase was present in the control hearts, but reversed in
the mutant SclCreERT;Brg1fl/fl hearts (Fig. 3L). Also, despite the car-
diac changes of angiotensin, Brg1 mutation caused no change of Ang
II in the plasma (Fig. 3M). These findings are consistent with cardiac
Ang I and II being primarily produced locally (11–14) and that such
local angiotensin production is regulated by cardiac endothelial Brg1.
Collectively, the results indicate that endothelial Brg1 responds to
cardiac stress to activate Ace and repress Ace2 expression, triggering a
pathological switch of Ace and Ace2 in stressed hearts.
Brg1 Binds to the Promoters of Ace and Ace2 to Regulate Their Expression.
To determine whether Brg1 directly regulated Ace and Ace2 ex-
pression in the stressed hearts, we first examined the binding of Brg1
to Ace and Ace2 promoters. With sequence alignment, we identified
four regions (a1–a4) in the ∼3-Kb upstream region of the mouse Ace
promoter that are evolutionarily conserved in mouse, rat, and human
(Fig. 3N). Chromatin immunoprecipitation (ChIP) assay using
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Fig. 3. Endothelial Brg1 controls Ace/Ace2 expression and Ang I/II metabolism in stressed hearts. (A) Quantitation of Ace, Ace2, and Ace/Ace2 in control (Ctrl)
and SclCreERT;Brg1fl/fl (Mut) hearts after 7 d of sham or TAC operation. (B–E) Immunostaining of Ace (brown) in control (B and C) and SclCreERT;Brg1fl/fl (D and
E) hearts 7 d after sham or TAC operation. (Scale bars, 10 μm.) (F–I) Immunostaining of Ace2 (green) in control (F and G) and SclCreERT;Brg1fl/fl (H and I) hearts
7 d after sham or TAC operation. (Scale bars, 10 μm.) (J and K) Western blot analysis (J) and quantitation (K) of Ace and Ace2 proteins in control (Ctrl) and
SclCreERT; Brg1fl/fl (Mut) hearts 7 d after sham or TAC operation. P value: Student’s t test. Error bar: SEM. (L andM) ELISA analysis of Ang I and II concentrations
in the heart (L) and plasma (M) 4 wk after TAC. Ctrl, control; Mut, SclCreERT;Brg1fl/fl. P value: Student’s t test. Error bar: SEM. (N) Sequence alignment of the
Ace locus from mouse, human, and rat. Peak heights indicate degree of sequence homology. Black boxes (a1–a4) are regions of high sequence homology and
were further analyzed by ChIP. Red, promoter elements; yellow, untranslated regions; green, transposons/simple repeats. (O) ChIP-qPCR analysis of Ace
promoter using antibodies against Brg1 (J1 antibody) and hearts 7 d after sham or TAC operation. P value: Student’s t test. Error bar: SEM. (P) Sequence
alignment of Ace2 locus from mouse, human, and rat. Peak heights indicate degree of sequence homology. Black boxes (b1–b5) are regions of high sequence
homology and were further analyzed by ChIP. (Q) ChIP-qPCR analysis of Ace2 promoter using antibodies against Brg1 (J1 antibody) and hearts 7 d after sham
or TAC operation. P value: Student’s t test. Error bar: SEM. (R) Luciferase reporter assays of the Ace (−2,983 to +174 bp) and Ace2 (−7,063 to +786 bp) proximal
promoter in mouse cardiac endothelial cells. P value: Student’s t test. Error bar: SEM.
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anti-Brg1 antibody (34) showed that, in TAC-operated hearts Brg1
was highly enriched in three of a1–a4 regions (a2, a3, and a4),
compared with the sham-operated hearts (Fig. 3O). Additionally,
we analyzed the 5.5-kb upstream region of the mouse Ace2 pro-
moter, which contained five highly conserved regions among dif-
ferent species (b1–b5 in Fig. 3P). ChIP analysis of the TAC-stressed
heart ventricles showed that Brg1 was highly enriched in three
of the b1–b5 regions (b2, b3, and b4), compared with the sham-
operated hearts (Fig. 3Q). These ChIP studies of stressed hearts
indicate that Brg1, once activated by stress, binds to evolutionarily
conserved regions of Ace and Ace2 proximal promoters.
We next tested the transcriptional activity of Brg1 on Ace and
Ace2 promoters. We cloned Ace upstream promoter (−2,983 to
+174 bp) and Ace2 upstream promoter (−7,063 to +786 bp) into the
episomal reporter pREP4 that allows promoter chromatinization in
mammalian cells (24, 35). We then transfected the reporter and
Brg1-expressing plasmids into mouse cardiac (coronary) endothelial
cells for reporter assays (36). In these cells Brg1 caused 1.7-fold in-
crease in Ace promoter activity and 59% reduction in Ace2 promoter
activity (Fig. 3R). These reporter studies, combined with the ChIP
results, indicate that Brg1 activates the Ace promoter and represses
the Ace2 promoter. This finding provides a molecular explanation
for the antithetical changes of Ace and Ace2 in stressed hearts.
Endothelial FoxM1 Is Required for Stress-Induced Cardiac Hypertrophy
and Pathological Ace/Ace2 Switch. We next hypothesized that
FoxM1 (a forkhead box transcription factor) was the transcription
factor that worked with Brg1 to antithetically regulate Ace and
Ace2 expression and contribute to cardiac hypertrophy. This hy-
pothesis was based on the following observations. First, FoxM1
regulates the expression of genes associated with pathological
hypertrophy (37, 38). Second, the FoxM1 protein contains both
transactivation and repressor domains, capable of functioning as a
transcription activator or repressor (25–27). Third, we found that
FoxM1 had expression dynamics in fetal, normal adult, and
stressed adult hearts, similar to that of Brg1. RT-qPCR and
immunostaining of heart ventricles showed that FoxM1 was
abundant in fetal hearts (Fig. S6A), but its expression was down-
regulated in normal adult hearts. In contrast, in TAC-stressed
hearts, FoxM1 mRNA increased by 8.4-fold (Fig. 4A), and the
proteins were up-regulated in the nuclei of both cardiomyocytes
and endothelial cells of stressed hearts (Fig. 4 B and C and Fig. S6
B and C). Western blot analysis of isolated cardiac endothelial
cells and cardiomyocytes showed that FoxM1 protein was up-
regulated by 2.5- and 2.3-fold after stress (Fig. 4 D and E and Fig.
S6 D and E).
We then tested the necessity of FoxM1 activation for cardiac
hypertrophy by using the FoxM1 inhibitor thiostrepton (39, 40) in
TAC-stressed hearts. Within 4 wk after TAC, the control mice
injected with the vehicle (DMSO) developed severe cardiac hy-
pertrophy with increased ventricle–body weight ratio, interstitial
fibrosis, and cardiac dysfunction with reduced left ventricular FS
(Fig. 4 F–I). In contrast, thiostrepton-treated mice exhibited mild
cardiac hypertrophy (Fig. 4F), mild interstitial fibrosis (Fig. 4 G
and H), and a lesser degree of cardiac dysfunction (Fig. 4I). There
was a ∼50% reduction of hypertrophy and 28% improvement of
FS, comparable to the improvement observed in endothelial Brg1-
null hearts (Fig. 2 F and J). In addition, Western blot analysis of
heart ventricles showed that TAC-induced Ace and Ace2 switches
were abolished when FoxM1 was inhibited by thiostrepton, with
the Ace/Ace2 ratio reduced by 6.5-fold in stressed hearts (Fig. 4 J
and K). This finding suggests that FoxM1 is required for the
pathological switch of Ace and Ace2.
To test the genetic role of FoxM1 in endothelial cells, we
crossed SclCreERT mice (31) with mice that carried floxed FoxM1
alleles (41) to generate the SclCreERT;FoxM1fl/fl mouse line. This
line enabled tamoxifen-induced deletion of FoxM1 in endothelial
cells. In tamoxifen-treated, TAC-operated SclCreERT;FoxM1fl/fl
hearts, FoxM1 protein was absent in endothelial cells, but not in
cardiomyocytes (Fig. 4 L andM), indicating an endothelial knockout
of FoxM1. Within four weeks after TAC, SclCreERT;FoxM1fl/fl mice
displayed ∼50% reduction of cardiac mass (ventricular/body weight
ratio reduced from 68% to 36%, P < 0.01) (Fig. 4N) and ∼55%
reduction of cardiomyocyte size measured by WGA staining (from
69% to 31%, P < 0.01) (Fig. S6 F–J). Also, SclCreERT;FoxM1fl/flmice
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Fig. 4. Endothelial FoxM1 is essential for cardiac hypertrophy and pathological
switch of Ace/Ace2. (A) Quantitation of FoxM1mRNA in mouse hearts after 7 d
after sham or TAC operation. (B and C) Coimmunostaining of FoxM1 (red) and
Pecam (green) in mouse hearts 7 d after sham or TAC operation. Arrows, en-
dothelial cell nuclei; arrowheads, myocardial cell nuclei. (Scale bars, 10 μm.) (D
and E) Western blot analysis (D) and quantitation (E) of FoxM1 proteins in
cardiac endothelial cells isolated from mouse hearts 7 d after sham or TAC
operation. P value: Student’s t test. Error bar: SEM. (F) Quantitation of ventricle–
body weight ratio of mice treated with DMSO (Ctrl) and thiostrepton (Thio)
after 4 wk of sham or TAC operation. (G and H) Trichrome staining of cardiac
fibrosis in mice treated with DMSO (Ctrl) and thiostrepton (Thio) after 4 wk
sham or TAC operation. Red, cardiomyocytes; blue, fibrosis. Arrow, interstitial
space. (Scale bars, 20 μm.) (I) Echocardiographic measurement of FS of the LV
after 4 wk (4W) of TAC. Ctrl, DMSO; Thio, thiostrepton. (J and K) Western blot
analysis (J) and quantitation (K) of Ace and Ace2 proteins in the heart of DMSO-
treated (Ctrl) and thiostrepton-treated (Thio) mice 2 wk (2W) after sham or TAC
operation. (L and M) Coimmunostaining of FoxM1 (red) and Pecam (green) in
control (Ctrl) and SclCreERT;FoxM1fl/fl mouse hearts 4 wk after TAC operation
with tamoxifen treatment. Arrows, endothelial cell nuclei; arrowheads, myo-
cardial cell nuclei. (Scale bars, 10 μm.) (N) Quantitation of ventricle–body weight
ratio in control (Ctrl) and SclCreERT;FoxM1fl/fl (Mut) mice 4 wk after sham or TAC
operation. P value: Student’s t test. Error bar: SEM. (O) Echocardiographic
measurement of FS of the left ventricle of control (Ctrl) and SclCreERT;FoxM1fl/fl
(Mut) hearts after 4 wk of TAC. P value: Student’s t test. Error bar: SEM. (P and
Q) Trichrome staining of cardiac fibrosis in control (P) and SclCreERT;FoxM1fl/fl (Q)
mice 4 wk after sham or TAC operation. Original magnification: 200×. Red,
cardiomyocytes; blue, fibrosis. (R) Representative LV pressure–volume (PV) loops
taken after cardiac catheterization of control (Ctrl) and SclCreERT; FoxM1fl/fl
(Mut) mice 4 wk after sham or TAC operation. (S) Quantitation of Ace, Ace2,
and Ace/Ace2 mRNA in control (Ctrl) and SclCreERT;FoxM1fl/fl (Mut) heart ven-
tricles after sham or TAC operation. P value: Student’s t test. Error bar: SEM.
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showed ∼50% improvement of left ventricular FS by echocardi-
ography (P = 0.02) (Fig. 4O) and a dramatic reduction of stress-
induced interstitial fibrosis (Fig. 4 P and Q). A complete charac-
terization of heart function by cardiac catheterization further
validated that endothelial FoxM1 deletion greatly improved the
function of TAC-stressed hearts (Fig. 4R). Endothelial FoxM1
deletion improved EF of the stressed hearts by 49%, SV by 32%,
CO by 28%, and plPwr by 54% (Fig. S7 A–D). The left ventricular
ESV was reduced by 32% (P < 0.01), and end-diastolic volume
was reduced by 11% (P = 0.03). The stress-induced changes of
diastolic relaxation (Tau) were reduced by 34% (Fig. S7 E–G),
and the left ventricular filling pressure (EDP) was reduced by 38%
(P < 0.01) (Fig. S7H). These findings indicate that endothelial
FoxM1 disruption prevents the development of cardiac dysfunc-
tion in stressed hearts. Furthermore, the TAC-induced patholog-
ical Ace/Ace2 switch was abolished with Ace/Ace2 ratio normalized
in those hearts lacking endothelial FoxM1 (Fig. 4S). These findings
indicate that activation of endothelial FoxM1 expression is essen-
tial for stress-induced cardiac hypertrophy and the pathological
Ace/Ace2 switch.
Brg1 Cooperates with FoxM1 in the Endothelium to Control Cardiac
Ace and Ace2 Expression. Given that both FoxM1 and Brg1 could
regulate Ace/Ace2 switch in stressed cardiac endothelium, we
tested whether there was a direct physical interaction between
these two proteins. We found that Brg1 coimmunoprecipitated
with FoxM1 in stressed heart ventricles (Fig. 5A). Proximity liga-
tion (Duolink) assay (42, 43) further confirmed that Brg1 and
FoxM1 formed a protein complex in the nuclei of mouse cardiac
endothelial cells (Fig. 5 B and C). We then asked whether FoxM1,
like Brg1, could bind to the promoters of Ace and Ace2 in stressed
hearts. ChIP analysis showed that FoxM1 was highly enriched in
the conserved regions of Ace and Ace2 proximal promoters of
TAC-stressed hearts relative to the sham-operated hearts (Fig. 5
D and E). The binding pattern of FoxM1 was broadly similar to
that of Brg1 (Fig. 3M and O). Given that DNA elements could be
looped and brought together by proteins bound to them and that
Brg1 and FoxM1 formed a physical complex in stressed endo-
thelial cells, the results suggest that Brg1 and FoxM1 form a
protein complex on Ace and Ace2 promoters to orchestrate reg-
ulatory DNA elements to control Ace and Ace2 expression. Fur-
thermore, luciferase reporter assays conducted in mouse cardiac
endothelial cells showed that FoxM1, like Brg1, was capable of
activating Ace and repressing Ace2 promoter activities (Fig. 5 F
and G). Inhibition of FoxM1 by thiostrepton (39, 40) eliminated
Brg1-mediated Ace promoter activation and Ace2 promoter re-
pression (Fig. 5 F andG). Likewise, knockdown of Brg1 abolished
FoxM1’s activity on Ace activation and Ace2 repression (Fig. 5 F
and G). These results indicate that Brg1 and FoxM1 are mutually
dependent for the regulation of Ace and Ace2 promoters. To
determine whether FoxM1 used different effector domains to
control Ace and Ace2 expression, we constructed two mutated
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Fig. 5. Brg1 cooperates with FoxM1 to control Ace and Ace2 expression.
(A) Coimmunoprecipitation of Brg1 with FoxM1 in heart ventricles after 7 d
of TAC. (B and C) Proximity ligation assay of Brg1–FoxM1 complex in nuclei
of cultured mouse cardiac endothelial cells. Original magnification: 400×.
Red, proximity ligation signal; blue, DAPI. IgG control, cells treated with IgG but
not primary anti-Brg1 or -FoxM1 antibodies. (D and E) ChIP-qPCR analysis of
Ace (D) and Ace2 (E) promoters using antibodies against FoxM1 7 d after
sham or TAC operation. (F and G) Luciferase reporter assays of the Ace
(−2,983 to +174 bp) (F) and Ace2 (−7,063 to +786 bp) (G) proximal pro-
moters (described in Fig. 3 L and N) in mouse cardiac endothelial cells. siBrg1,
siRNA-mediated knockdown of Brg1; Thio, thiostrepton. P value: Student’s t
test. Error bar: SEM. (H) Schematic illustration of FoxM1 repression, trans-
activation domains, and mutations. NRD, N-terminal repression domain;
TAD, C-terminal transactivation domain. (I and J) Luciferase reporter assays
of the Ace (I) and Ace2 (J) promoters with FoxM1 mutants in mouse cardiac
endothelial cells. P value: Student’s t test. Error bar: SEM.
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Fig. 6. BRG1 and FOXM1 activation in human cardiomyopathy. (A) qPCR
analysis of BRG1, FOXM1, ACE, and ACE2 expression and ACE/ACE2 ratio in
normal (n = 7) and LVH hearts (n = 4). (B and C) Coimmunostaining of BRG1
(red) and WGA (green) in normal and LVH hearts. Arrow, endothelial cell;
arrowhead, myocardial cell. (Scale bars, 10 μm.) (D and E) Coimmunostaining
of FOXM1 (red) and WGA (green) in heart of normal and LVH subjects. Arrow,
endothelial cell; arrowhead, myocardial cell. (Scale bars, 10 μm.) (F) Correlation
of BRG1 and FOXM1 mRNA level (x axis) with ACE/ACE2 mRNA ratio (y axis),
n = 11. Red, nonlinear regression curve. e, the base of natural logarithm
(∼2.718). Equations of Boltzmann sigmoidal model are listed under the graphs.
(G) Working model of how cardiac endothelial Brg1–FoxM1 complex mediates
stress signals to control Ace/Ace2 and angiotensin production in the heart.
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FoxM1 proteins: FoxM1 with C-terminal transactivation domain
truncated (ΔTAD) and FoxM1 with N-terminal repression do-
main truncated (ΔNRD) (refs. 44 and 45 and Fig. 5H). Without
the transactivation domain, the FoxM1–ΔTAD mutants failed to
activate the Ace promoter, but maintained its repression of the
Ace2 promoter (Fig. 5 I and J). Conversely, without the repressor
domain, FoxM1–ΔNRD mutants failed to repress the Ace2 pro-
moter, but preserved effects on Ace promoter activation (Fig. 5 I
and J). These results indicate that FoxM1 functions through dif-
ferent transcriptional effector domains for the regulation of Ace
and Ace2 promoters, providing a molecular explanation for the
antithetical effects of the Brg1–FoxM1 complex on Ace and Ace2.
Overall, the ChIP and reporter analyses, combined with the stress-
induced formation of the Brg1–FoxM1 complex, suggest that Brg1
and FoxM1 cooperate to regulate the pathological switch of Ace
and Ace2 in the stressed heart.
Implications for Human Cardiac Hypertrophy. To investigate whether
BRG1 and FOXM1 were also activated in the endothelial cells of
human hypertrophic hearts, we studied patients with left ventric-
ular hypertrophy (LVH). The tissue samples were obtained from
donor hearts that were considered unsuitable for transplantation
because of the lack of timely recipients or mismatched surgical cut
(Fig. S8). RT-qPCR of mRNA showed that the human hyper-
trophic hearts had a 2.1- and 2.6-fold increase of FOXM1 and
BRG1, a 3.4-fold increase of ACE, and a 51% reduction of ACE2,
with the ACE/ACE2 ratio increased by 6.7-fold (Fig. 6A). Like in
mice, BRG1 and FOXM1 were up-regulated in both car-
diomyocytes and endothelial cells of the hypertrophic hearts (Fig.
6 B–E). Nonlinear regression analysis showed that the level of
BRG1 and FOXM1 correlated strongly with the level of patho-
logical switch of ACE/ACE2 in human hearts (Fig. 6F; r2 = 0.848
and 0.995, respectively). The human tissue studies thus suggest an
evolutionarily conserved mechanism underlying myopathy of
mouse and human hearts.
Discussion
Controlling Ace/Ace2 expression is critical for maintaining cardiac
function, given that an increase of Ace or reduction of Ace2 is
sufficient to cause cardiomyopathy (20, 23, 46). We showed that
the Ace and Ace2 amount in the heart is controlled primarily at the
transcription level and identified an endothelial chromatin complex
composed of Brg1 and FoxM1 that transcriptionally activates Ace
and represses Ace2 in response to cardiac stress (Fig. 6G). This
finding provides new molecular insights into endothelial–myocar-
dial interaction under pathological conditions. The requirement of
the Brg1–FoxM1 complex for pathological hypertrophy has im-
portant implications for heart failure therapy. In stressed hearts, a
chemical inhibitor of FoxM1 is effective in reversing Ace/Ace2 and
preventing cardiac hypertrophy and dysfunction. It is therefore
pharmacologically feasible to inhibit Ace and activate Ace2 si-
multaneously to improve heart function. Given that there has not
been an effective chemical activator of Ace2, likely because of the
difficulty of generating protein activators of any kind, chemical
inhibition of Brg1–FoxM1 complex reveals a new avenue for
pharmacologically targeting Ace and Ace2 genes simultaneously to
reverse Ace/Ace2 ratio in failing hearts. Besides Ace/Ace2 regula-
tion, broader functions of the endothelial Brg1–FoxM1 complex
will require a future genome-wide approach to determine other
downstream targets of this complex in stressed hearts.
At the molecular level, Brg1 and FoxM1 interactions show a
molecular mechanism for Brg1 and FoxM1 in gene regulation.
The FoxM1 protein contains both a transactivating and a re-
pressor domain for transcription regulation. How such dual tran-
scription activity of FoxM1 is controlled remains unclear. We
showed here that Brg1 is essential for FoxM1 to repress Ace and
to activate Ace2. However, it remains unknown how Brg1 enables
FoxM1 to use its repressor domain on one promoter (such as Ace)
and its transactivating domain on another promoter (such as
Ace2). Such promoter-specific activity of FoxM1 may be caused by
how Brg1 rearranges the chromatin–DNA for FoxM1 to bind or
by other unidentified factors in the promoter that differentially
expose or enable the FoxM1 transactivating or repressor domain.
Given that FoxM1 is required for embryogenesis and is a proto-
oncogene up-regulated in many human cancers, including lung,
breast, and colon cancers (25–27, 47), future studies to define the
molecular details of the differential domain use of FoxM1 may
have important implications in organ development, cardiac hy-
pertrophy, and many other diseases.
Materials and Methods
Brg1fl/fl, FoxM1fl/fl, and SclCreERT [endothelial-SCL-Cre-ERT (31)] mice have
been described (32, 48–50). Littermate CD1 male mice were purchased from
Charles River (strain code 022). Animal use protocol was reviewed and approved
by Indiana University Institutional Animal Care and Use Committee (IACUC).
Only de-identified human tissues were used for studies. The human tissues were
processed for RT-qPCR. The use of human tissues is in compliance with the
regulation of Sanford/Burnham Medical Research Institute and Indiana Uni-
versity. Informed consent procedures were in compliance with Institutional
Biosafety Committee protocol (no. 1784) approved by Indiana University. Curve
modeling was performed with the Levenburg–Marquardt nonlinear regression
method and XLfit software.
Additionalmaterials and procedures are provided in SIMaterials andMethods.
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